Investigating Aß42, P‐Tau and NFL as blood‐based biomarkers for diagnosis of Alzheimer’s disease in Pakistani population

Overlapping symptoms of different neurodegenerative dementias and heterogeneity in the presentation of Alzheimer’s disease (AD) pose a challenge to its diagnosis in clinics. The AT(N) research framework proposed by National Institute of Ageing‐Alzheimer’s Association in 2018 assigned its diagnosis a molecular construct. However, in Pakistan the diagnosis of AD still rests on clinical exclusionary approach. As an initial step towards establishing accessible and affordable biochemical diagnosis of AD in Pakistan, we for the first time investigated the plasma levels of Amyloid‐β42 (Aβ42), Phosphorylated tau (P‐tau) and Neurofilament light (NFL) in patients with Alzheimer’s Clinical Syndrome (ACS) and healthy controls (HC) from Pakistani population.